VYNT earnings

Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered platform and poster presentations at the 2022 CDKL5 Forum hosted by the Loulou FoundationEntered into a master services agreement and related statement of work with an Australian CRO in November 2022 to support the Company's adult Rett Syndrome clinical trialProgress with licensing our iPSC technology to transition key product sales customers Q3 2022 Financial Highlights $9.4 million of cash and equivalents as of September 30, 2022Current cash balances, net proceeds from the sale of

Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into clinical trials in Rett patients with encouragement and guidance from the International Rett Syndrome FoundationContinued progress with efforts towards the divestiture of the vivoPharm businessProgress with licensing our iPSC technology to transition key product sales customers Financial Highlights $11.7 million of cash and equivalents as of June 30, 2022Cash runway approximately 18 months CHERRY HILL, N.J., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (N

CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will release its financial results for the second quarter and first half ended June 30, 2022, on Monday, August 22, 2022. Vyant Bio will host an investor conference call and webcast on Monday, August 22, 2022 at 4:30 pm ET. Jay Roberts, Chief E

CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it is postponing its investor conference call for the second quarter and first half of 2022, originally scheduled for Monday, August 15, 2022 at 4:30 pm ET. Very recent developments related to the accounting for the potential sale of its vivoPharm s

CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's proprietary central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that it will release its financial results for the second quarter and first half ended June 30, 2022, on Monday, August 15, 2022. Vyant Bio will host an investor conference call and webcast on Monday, August 15, 2022 at 4:30 pm ET. Jay Roberts, Chief E

Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights  ●Progress in the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative diseases for Rett Syndrome ("Rett"), CDKL5 Deficiency Disorder ("CDD"), and familial Parkinson's Disease    ●Identification of a clinical candidate for Rett Syndrome through a robust rescue of disease phenotype in vitro using proprietary high throughput screening technology resulting in a potentially unique mechanism from other advanced therapeutic candidates    ●Entered a collaboration with OrganoTherapeutics to accelerate 3D organoid disease modeling and identification of novel therapeutics

CHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Monday, May 16, 2022. Jay Roberts, Chief Executive Officer, Andy LaFrence, Chief Financial Officer, and Robert Fremeau, PhD, Chief Scientific Officer, of Vyant Bio will provide an update on the busine

Highlights Focused as a pure-play drug discovery and development biotechnology companyPrimary work on the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative diseases for Rett Syndrome ("Rett"), CDKL5 Deficiency Disorder ("CDD"), and familial Parkinson's DiseaseStreamlined the business focus; pursuing the divestiture of wholly-owned subsidiary vivoPharm to exit CRO services business to focus on drug discoveryEntered into a strategic collaboration with Organo Therapeutics to accelerate 3D organoid disease modeling and identification of novel therapeutics to treat familial Parkinson's Disease in Q1, 2022Cash position at December 31, 2021 was $20.6 millio

CHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company's central nervous system ("CNS") drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Wednesday, March 30, 2022. Jay Roberts, Chief Executive Officer, Andy LaFrence, Chief Financial Officer and Robert T. Fremeau, PhD, Chief Scientific Officer of Vyant Bio will discuss the Year-End 2021

Strategic Highlights Hired Robert Fremeau, Jr., PhD as Chief Scientific Officer to lead Vyant Bio's R&D programs targeting the identification of novel therapeuticsEntered into two new first phase feasibility programs with leading biopharma companies to demonstrate Vyant Bio's human-derived discovery platform technology for identifying novel biological targets and novel compoundsCompleted a second large screening of artificial intelligence ("AI") -generated novel compounds for Rett Syndrome, in conjunction with its collaboration partner Atomwise, yielding promising results, including further hit expansion across two unique biological targets and several novel compoundsEntered into a collab

CHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Thursday, November 11, 2021. Jay Roberts, Chief Executive Officer, and Andy LaFrence, Chief Financial Officer, of Vyant Bio will highlight corporate, scientific, financial, and operational results achieved in the third quarter of 2021. Please also visit the Investors section of the Vyant Bio web site for details on how to p

Strategic Highlights Received an issued US Patent titled "High Throughput Optical Assay of Human Mixed Cell Population Spheroids" by the United States Patent and Trademark Office (USPTO). The patent covers the use of spheroids and organoids for drug discovery.Entered into a strategic collaboration with Ordaōs Bio and Cellaria, Inc. to execute an integrated model for rapid iteration of therapeutic design using artificial intelligence ("AI") and human-derived in vitro ‘avatar clinical trials' to enable the design, development, and testing of potential therapeutics on targeted patient populations, during preclinical discovery with a primary focu

CHERRY HILL, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. With leading-edge capabilities in data science, biological and chemical sciences, engineering, and regulatory affairs, Vyant Bio capitalizes on in silico, human cell-derived in vitro disease models, and in vivo discovery technologies to identify novel biological targets and valuable therapeutics for patients. Today, Vyant Bio announced that an investor conference call and webcast will be hosted on Monday, August